Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT-I7 and Pembrolizumab in Advanced Solid Tumors
NCT04332653Phase 2Completed
- Sponsor
- NeoImmuneTech
- Start
- Jun 2020
- Primary completion
- Nov 2024
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of efineptakin alfa in solid tumor, triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), colorectal cancer (CRC), sponsored by NeoImmuneTech. Started Jun 2020; status: completed.
02
Drugs
efineptakin alfa
03
Conditions
solid tumortriple-negative breast cancer (TNBC)non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04332653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04332653.